Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18905898 | METHOD OF TREATING HAIR LOSS DISORDERS | October 2024 | March 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18750014 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18750032 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | June 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18674104 | MIRDAMETINIB TREATMENT | May 2024 | June 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18674233 | MIRDAMETINIB TREATMENT | May 2024 | September 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18674168 | MIRDAMETINIB TREATMENT | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18601528 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | March 2024 | October 2024 | Allow | 7 | 0 | 1 | No | No |
| 18437335 | PRMT5 INHIBITORS AND METHODS OF USE | February 2024 | July 2024 | Allow | 5 | 0 | 0 | No | No |
| 18425466 | 3-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND | January 2024 | June 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18412758 | 6-AMINO-8,9-DI(4-METHOXYPHENYL)-2-OXO-3,9-DIHYDRO-2H-[1,3]THIAZOLO[5',4':5,6]PYRANO[2,3-B]PYRIDINE-7-CARBONITRILE AS ANTICANCER COMPOUND | January 2024 | June 2025 | Abandon | 17 | 2 | 0 | Yes | No |
| 18394703 | 3-(2-(4-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTI-CANCER COMPOUND | December 2023 | June 2025 | Abandon | 17 | 2 | 0 | No | No |
| 18538067 | JAK1 SELECTIVE INHIBITORS | December 2023 | July 2025 | Allow | 19 | 0 | 1 | No | No |
| 18529311 | PYRIDO[3',4':4,5]PYRROLO[3,2-C]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | January 2025 | Allow | 13 | 1 | 1 | No | No |
| 18526380 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18526408 | Spiropiperidine Derivatives | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18518127 | MIRDAMETINIB TREATMENT | November 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18385742 | IMIDAZOPYRIDAZINE COMPOUNDS AND USES THEREOF | October 2023 | July 2025 | Allow | 20 | 0 | 1 | No | No |
| 18237152 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18225966 | THERAPEUTIC COMPOUNDS | July 2023 | June 2025 | Allow | 23 | 1 | 0 | No | No |
| 18204149 | Methods and Compositions for Treating Melanoma and Non-Melanoma Skin Cancers | May 2023 | May 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18320805 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | May 2023 | March 2025 | Allow | 22 | 1 | 1 | No | No |
| 18196357 | SPIRO AROMATIC RING COMPOUND AND USE THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18314913 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | May 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18143765 | CRYSTALLINE (R)-5-CARBAMOYLPYRIDIN-3-YL-2-METHYL-4-(3-(TRIFLUOROMETHOXY)BENZYL)PIPERAZINE-1-CARBOXYLATE, COMPOSITIONS AND METHODS OF USE THEREOF | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18311646 | Small Molecule Inhibitors of KRAS G12C Mutant | May 2023 | December 2024 | Allow | 20 | 0 | 1 | Yes | No |
| 18311639 | Small Molecule Inhibitors of KRAS G12C Mutant | May 2023 | December 2024 | Allow | 20 | 0 | 1 | Yes | No |
| 18140730 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18135607 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | April 2023 | May 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18134843 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | April 2023 | February 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18131226 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | April 2023 | April 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18088045 | DIHYDROINDOLIZINONE DERIVATIVE | December 2022 | March 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18062295 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | December 2022 | January 2025 | Allow | 25 | 0 | 1 | Yes | No |
| 18060796 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | December 2022 | February 2025 | Abandon | 26 | 1 | 0 | No | No |
| 17924537 | USE OF AMINOACETONITRILE COMPOUNDS FOR THE TREATMENT OF INFECTION AND DISEASE | November 2022 | September 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17959799 | COMPOUNDS AND THEIR METHODS OF USE | October 2022 | February 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17946181 | HETEROCYCLIC RIP1 KINASE INHIBITORS | September 2022 | January 2025 | Allow | 28 | 1 | 1 | No | No |
| 17908296 | ELASTASE INHIBITOR PRODRUG AND USE THEREOF | August 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17822871 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | August 2022 | June 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17867229 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | July 2022 | April 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17863236 | PYRIDINIUM SALT AND PEST CONTROL AGENT | July 2022 | April 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17861023 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | July 2022 | March 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17853904 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | June 2022 | July 2024 | Allow | 24 | 1 | 1 | No | No |
| 17839215 | G1T38 SUPERIOR DOSAGE REGIMES | June 2022 | March 2025 | Allow | 33 | 1 | 1 | No | No |
| 17836255 | ANTIBACTERIAL COMPOUNDS | June 2022 | February 2025 | Allow | 32 | 1 | 1 | No | No |
| 17781167 | FLUORINE-CONTAINING HETEROCYCLIC DERIVATIVES WITH MACROCYCLIC STRUCTURE AND USE THEREOF | May 2022 | June 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17827547 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | May 2022 | September 2024 | Allow | 28 | 0 | 1 | Yes | No |
| 17779091 | TRI-HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND USE THEREOF | May 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17736924 | NOVEL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | May 2022 | January 2025 | Allow | 33 | 1 | 1 | No | No |
| 17773418 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | April 2022 | April 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17772993 | TETRAHYDROCANNABINOL DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF | April 2022 | June 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17731279 | NLRP3 MODULATORS | April 2022 | August 2024 | Allow | 27 | 0 | 1 | No | No |
| 17772093 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | April 2022 | May 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17728943 | PROTEASE INHIBITORS | April 2022 | March 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17659269 | Elagolix Sodium Compositions and Processes | April 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17709847 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | March 2022 | February 2025 | Allow | 35 | 1 | 1 | No | No |
| 17709242 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS | March 2022 | June 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17651187 | DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX | February 2022 | July 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17582851 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | January 2022 | June 2024 | Allow | 28 | 1 | 1 | No | No |
| 17617956 | METHOD FOR PREPARING CHOLESTEROL, DERIVATIVE THEREOF, AND ANALOG THEREOF | December 2021 | June 2025 | Allow | 42 | 0 | 1 | No | No |
| 17545664 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | December 2021 | March 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17537298 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | November 2021 | June 2024 | Allow | 30 | 1 | 1 | No | No |
| 17609392 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | November 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17497355 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | October 2021 | February 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17423482 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | July 2021 | August 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17421303 | ORGANIC COMPOUNDS | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17359205 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | June 2021 | January 2025 | Allow | 43 | 1 | 1 | No | No |
| 17414408 | POLYCYCLIC COMPOUND INHIBITING MNK1 AND MNK2 | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17292699 | COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT | May 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17292363 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | May 2021 | October 2024 | Allow | 41 | 0 | 1 | No | No |
| 17244767 | TUBULIN INHIBITORS | April 2021 | September 2024 | Allow | 41 | 1 | 0 | No | No |
| 17277649 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | March 2021 | January 2025 | Allow | 46 | 1 | 1 | No | No |
| 17270480 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | February 2021 | September 2024 | Allow | 43 | 0 | 1 | No | No |
| 17140789 | COMPOSITIONS USEFUL IN THERAPY OF AUTOPHAGY-RELATED PATHOLOGIES, AND METHODS OF MAKING AND USING THE SAME | January 2021 | August 2024 | Allow | 43 | 1 | 1 | No | No |
| 17088613 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | November 2020 | April 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 16582510 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | September 2019 | January 2020 | Allow | 4 | 1 | 0 | No | No |
| 16465277 | TUMOR-TREATING PHARMACEUTICAL COMPOSITION | May 2019 | June 2020 | Allow | 13 | 1 | 0 | Yes | No |
| 16401834 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | May 2019 | April 2020 | Allow | 11 | 0 | 1 | Yes | No |
| 16376858 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | April 2019 | March 2020 | Allow | 11 | 1 | 0 | No | No |
| 16370857 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | March 2019 | October 2019 | Allow | 7 | 0 | 0 | No | No |
| 16294372 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | March 2019 | January 2020 | Allow | 11 | 0 | 1 | No | No |
| 16324189 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | February 2019 | June 2020 | Allow | 16 | 0 | 1 | Yes | No |
| 16246745 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | January 2019 | January 2020 | Allow | 12 | 1 | 1 | Yes | No |
| 16243782 | COVALENT INHIBITORS OF CDK-7 | January 2019 | June 2019 | Allow | 5 | 0 | 0 | No | No |
| 16145271 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | September 2018 | January 2019 | Allow | 3 | 0 | 0 | No | No |
| 16079764 | NEW CRYSTALLINE FORMS OF (6-(1H-INDAZOL-6-YL)-N-[4-(4-MORPHOLINYL)PHENYL]IMIDAZO[1,2-A]PYRAZIN-8-AMINE) METHANESULFONATE | August 2018 | July 2019 | Allow | 11 | 1 | 0 | Yes | No |
| 16101250 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | August 2018 | January 2020 | Allow | 17 | 1 | 1 | No | No |
| 16072116 | PYRROLOBENZODIAZEPINES | July 2018 | April 2019 | Allow | 9 | 0 | 0 | No | No |
| 15993937 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | May 2018 | June 2019 | Allow | 13 | 1 | 0 | No | No |
| 15763389 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | March 2018 | August 2019 | Allow | 16 | 1 | 1 | No | No |
| 15759950 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | March 2018 | March 2019 | Allow | 12 | 1 | 0 | No | No |
| 15756366 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | February 2018 | January 2019 | Allow | 11 | 1 | 0 | No | No |
| 15903285 | INHIBITORS OF BRUTON'S TYROSINE KINASE | February 2018 | March 2019 | Allow | 13 | 1 | 1 | No | No |
| 15753264 | HIV-1 PROTEASE INHIBITORS AND USES THEREOF | February 2018 | July 2019 | Allow | 16 | 1 | 1 | No | No |
| 15749950 | Benzodiazepines as bromodomain inhibitors | February 2018 | August 2018 | Allow | 6 | 0 | 0 | No | No |
| 15877524 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | January 2018 | June 2018 | Allow | 5 | 0 | 1 | No | No |
| 15746617 | COMPOUND HAVING EP2 AGONIST ACTIVITY | January 2018 | May 2019 | Allow | 16 | 1 | 1 | Yes | No |
| 15841002 | TRICYCLIC COMPOUND AND JAK INHIBITOR | December 2017 | April 2019 | Allow | 16 | 2 | 1 | No | No |
| 15801192 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | November 2017 | December 2018 | Allow | 14 | 0 | 1 | Yes | No |
| 15795801 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | October 2017 | April 2019 | Allow | 18 | 1 | 1 | No | No |
| 15719924 | HESPERETIN AZA-CINNAMIC ACID DERIVATIVES WITH ANTI-TUMOR ACTIVITIES AND A METHOD OF PREPARING THE SAME | September 2017 | July 2018 | Allow | 9 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEESER, ERICH A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEESER, ERICH A works in Art Unit 1622 and has examined 696 patent applications in our dataset. With an allowance rate of 81.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner LEESER, ERICH A's allowance rate of 81.2% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LEESER, ERICH A receive 1.04 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEESER, ERICH A is 26 months. This places the examiner in the 59% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +20.8% benefit to allowance rate for applications examined by LEESER, ERICH A. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 44.7% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 69.2% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 37.7% are granted (fully or in part). This grant rate is in the 35% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 10.5% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.7% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.